Gastrointestinal Toxicity of Vorinostat in Combination with Pelvic Radiotherapy
Author Information
Author(s): Bratland Åse, Dueland Svein, Hollywood Donal, Flatmark Kjersti, Ree Anne H
Primary Institution: Norwegian Radium Hospital - Oslo University Hospital
Hypothesis
Does the dose distribution within the irradiated bowel volume affect the development of dose-limiting toxicity (DLT) in patients receiving vorinostat with pelvic radiotherapy?
Conclusion
The study suggests that radiation dose-volume effects should be quantified to fully interpret the toxicity profile of systemic targeted therapeutics used with radiotherapy.
Supporting Evidence
- Three patients experienced grade 3 gastrointestinal toxicities, indicating a common toxicity profile with radiotherapy.
- The maximum-tolerated dose of vorinostat was determined to be 300 mg once daily based on reported DLTs.
- Radiation dose-volume effects were significant in determining the toxicity profile of vorinostat when combined with pelvic radiotherapy.
Takeaway
This study looked at how a drug called vorinostat affects patients getting radiation therapy for cancer, especially focusing on stomach problems caused by the treatment.
Methodology
The study reanalyzed toxicity data from a phase 1 trial of vorinostat combined with pelvic radiotherapy, focusing on dose-volume effects in the small bowel.
Limitations
The study population was small, and the data is descriptive without statistical adaptation.
Participant Demographics
The study included 14 patients with advanced gastrointestinal carcinoma, with a mix of genders and ages ranging from 45 to 87 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website